ClinicalTrials.gg
CompletedNCT04376554Updated May 4, 2021

Effect of Tebipenem on Normal Human Intestinal Microbiota

A Phase 1 interventional study of TBPM-PI-HBr and amoxicillin-clavulanate in Healthy Volunteers, sponsored by Spero Therapeutics. Completed at 1 site in Sweden. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-04.

Sponsored by Spero Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2021, 5 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The overall purpose of this study is to support the development of an oral formulation of TBPM-PI-HBr by assessing the potential ecological effects of tebipenem on the normal intestinal microbiota as compared to the effects of oral amoxicillin-clavulanate.

Read the detailed description

This is a single-center, open-label, randomized, parallel-group, active-control, phase 1 study consisting of 10-day treatment period using TBPM-PI-HBr (600mg) (2× 300mg film coated tablets) or amoxicillin-clavulanate (500mg/125mg) orally every 8 hours (PO q8h [±1 hour]) in healthy volunteers. Participants will be randomized by gender to 1:1 ratio on Day 1. A maximum of 30 participants will be randomly assigned to the study treatment groups (15 in each arm) such that approximately 24 evaluable participants complete the study. Due to the multidimensional nature of data of the study, a power statement on a single endpoint is not appropriate. The main aim of the study is to estimate the effects of treatment on the intestinal microbiota, and to assess the pattern of susceptibility to specific pathogens. Based upon previous studies, a sample size of 12 participants in each group is considered sufficient to demonstrate a clinically significant impact of antibiotics on the microbiota. Total duration of study participation for each participant will be approximately 7 months.Screening visit will be performed between Day -28 to Day -1. Randomization will be performed on Day 1 and with treatment being administered from Day 1 to Day 10. Follow-up of participants will occur on Day 14, 21, 90 and 180 with appropriate visit windows. Adverse events and concomitant medications will be recorded until the end of the study (Day 180).

02

Conditions studied

  • Healthy Volunteers

Keywords

  • intestinal microbiota
  • safety
  • pharmacokinetics
  • TBPM-PI-HBr
  • tebipenem
03

In context

Lead sponsor

Spero Therapeutics is the lead sponsor of 22 studies on the registry; none are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 3 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult males and/or females, ≥18 years of age at the time of screening;
  2. Medically healthy without abnormal values for hematology, clinical chemistry, urinalysis, physical examination, vital signs, or as determined by the investigator during the screening period. Discussion is encouraged between the Investigator and the Sponsor Medical Monitor regarding the clinical relevance of any abnormal laboratory value during the pre-dose period;
  3. Willing and able to provide written ;
  4. Willing and able to comply with all study assessments and adhere to the protocol schedule, including all scheduled post-therapy visits;
  5. Have suitable venous access for blood sampling;
  6. Women of (WOCBP*) must use a highly effective form of (confirmed by the Investigator). Rhythm methods will not be considered as highly effective methods of birth control. WOCBP must agree to use a highly effective method of birth control, as defined above, from signing the Informed Consent Form (ICF), throughout the study duration and until 30 days after the last dose of study drug;
  7. Non-vasectomized male volunteers must use an adequate method of contraception (condom or condom with spermicide, depending on local regulations) from the time of signing the ICF, throughout the study duration and until 30 days after the last dose of study drug. Men with a partner who is (are) not of childbearing potential are exempt from these requirements;
  8. Male volunteers must not donate sperm for time of signing the ICF until at least 30 days after the last dose of the study drug

Exclusion criteria

Exclusion Criteria:

  1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or surgery within the past 3 months determined by the Investigator to be ;
  2. History or presence of known or suspected gastrointestinal disorder, including but not limited to Clostridioides difficile infection, inflammatory bowel disease, recent history of food poisoning or other stomach/intestinal disorders including gastroenteritis (within 6 months);
  3. History of systemic antibiotic treatment during the last three months prior to randomization;
  4. Use of any systemic prescription medication or any systemic over-the-counter medication, including herbal products and vitamins or probiotics within 7 days prior to randomization; except for hormonal and the intermittent use of paracetamol, ibuprofen, and antihistamines;
  5. (ALT) or aspartate transaminase (AST) >5 × and of ≤50 mL/min, as estimated by the Lund-Malmö revised formula;
  6. History of seizure disorders, except for febrile seizures in childhood;
  7. History of substance or alcohol abuse and positive urine drug testing at screening. History of substance or alcohol abuse and negative urine drug testing at screening can be enrolled in study based on the Investigator's discretion;
  8. Positive for (HIV), surface antigen (HBsAg), or antibodies (HCV);
  9. Documented or suspected reaction or anaphylaxis to β-lactam antibiotics (e.g., cephalosporins, penicillins, carbapenems), product (Mannitol, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and film coating systems [Opadry]) or any to the use of amoxicillin- clavulanate;
  10. Participation in another clinical study within 3 months prior to Day 1;
  11. Current or anticipated need for systemic antibiotics, probiotics, or laxatives during the study;
  12. Any other condition or prior therapy, which, in the opinion of the Investigator, would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likely to be non-compliant with any study requirements.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    TBPM-PI-HBr

    Healthy subjects meeting eligibility criteria will be sequentially randomized to receive either 600mg TBPM-PI-HBr every 8 hours (PO q8h \[±1 hour\]) or 500/125mg amoxicillin-clavulanate PO q8h (±1 hour) for 10 days.

    Drug: TBPM-PI-HBr

  • Active comparator
    amoxicillin-clavulanate

    Healthy subjects meeting eligibility criteria will be sequentially randomized to receive either 500/125mg amoxicillin-clavulanate PO q8h (±1 hour) or 600mg TBPM-PI-HBr every 8 hours (PO q8h \[±1 hour\]) or for 10 days.

    Drug: amoxicillin-clavulanate

Interventions

  • TBPM-PI-HBr (2 x 300mg tablets) PO q8h \[±1 hour\] for 10 days

    Also known as: TBPM-PI-HBr oral tablet

  • Drugamoxicillin-clavulanate

    Drug pages: Amoxicillin · Clavulanic Acid

    amoxicillin-clavulanate (1 × 500mg/125mg tablet) PO q8h \[±1 hour\] for 10 days

    Also known as: amoxicillin-clavulanate oral tablets

06

What researchers measure

Primary outcomes

  1. Changes in the number of microorganisms in the intestinal flora of healthy subjects during and after 10 days of oral administration of TBPM-PI-HBr or amoxicillin-clavulanate

    Changes in the number of microorganisms identified in feces

    Time frame: Change from baseline (Day-1), at Days 2, 4, 7, 10, 14, 21, 90, and 180

  2. Changes in the types of microorganisms in the intestinal flora of healthy subjects during and after 10 days of oral administration of TBPM-PI-HBr or amoxicillin-clavulanate

    Changes in the types of microorganisms identified in feces

    Time frame: Change from baseline (Day-1), at Days 2, 4, 7, 10, 14, 21, 90, and 180

Secondary outcomes

  1. To explore the potential for development of resistance by measuring the number of new colonizing bacterial isolates

    Emergence of resistant strains with increasing minimum inhibitory concentration values during treatment and post-treatment with tebipenem and amoxicillin-clavulanate will be determined from fecal samples.

    Time frame: Change from baseline (Day-1), at Days 2, 4, 7, 10, 14, 21, 90, and 180

  2. To assess the plasma concentrations of tebipenem over 10 days of oral administration of TBPM-PI-HBr.

    PK concentration of tebipenem will be measured in plasma. Concentrations of tebipenem will be plotted for each participant.

    Time frame: Day 1 through Day 14

  3. To assess the fecal concentrations of tebipenem over 10 days of oral administration of TBPM-PI-HBr.

    PK concentration of tebipenem will be measured in feces.Concentrations of tebipenem will be plotted for each participant.

    Time frame: Day 1 through Day 14

  4. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    To assess the incidents of treatment-emergent adverse events following 10 days of oral TBPM-PI-HBr administration

    Time frame: Incidents of treatment-emergent adverse events from Day 1 through last follow-up visit (180 days after last dose)

  5. Incidence of abnormal safety laboratory assessments [Safety and Tolerability]

    To assess the incidents of abnormal hematology, biochemistry, coagulation and urinalysis assessments following 10 days of oral TBPM-PI-HBr administration

    Time frame: Incidents of abnormal safety laboratory assessments from Day 1 through last follow-up visit (180 days after last dose)

  6. Incidence of abnormal vital sign assessments [Safety and Tolerability]

    To assess the incidents of abnormal heart rate, blood pressure and body temperature assessments following 10 days of oral TBPM-PI-HBr administration

    Time frame: Incidents of abnormal vital sign assessments from Day 1 through last follow-up visit (180 days after last dose)

  7. Incidence of abnormal physical exam assessments [Safety and Tolerability]

    To assess the incidents of abnormal body system assessments following 10 days of oral TBPM-PI-HBr administration

    Time frame: Incidents of abnormal physical exam assessments from Day 1 through last follow-up visit (180 days after last dose)

Other outcomes

  1. Correlation of intestinal microbiota patterns with tebipenem concentrations measured in feces.

    Measurement of concentrations of TBPM in feces using bioactivity techniques and correlate changes in microbiota as evidenced by various microbiological techniques (eg. microbial diversity, colony counts, and molecular methods).

    Time frame: Day 1 through last follow-up visit (180 days after last dose)

07

Study locations

1 site
  • Karolinska University Hospital
    Huddinge, Stockholm, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Apr 2021, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2020
First posted
May 6, 2020
StartActual
Feb 10, 2020
Primary completionActual
Apr 6, 2021
CompletionActual
Apr 6, 2021
Last update
May 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04376554
Lead sponsor
Spero Therapeutics
Collaborators
Iqvia Pty Ltd
Responsible party
Sponsor
First posted
May 6, 2020
Start date
Feb 10, 2020
Primary completion
Apr 6, 2021
Completion
Apr 6, 2021
Last update
May 4, 2021

Study contacts

Steffan Rosenborg
principal investigator · Karolinska Universitetssjukhuset

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tebipenem

Start the discussion